Should we use KRd or VRd for patients with NDMM?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked: Should we use carfilzomib, lenalidomide, and dexamethasone (KRd) or bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma (NDMM)? In this podcast he describes the results of the ENDURANCE (E1A11) phase III trial.
Shaji Kumar discusses the results of the primary endpoints: progression-free survival, and duration of therapy, as well as the secondary endpoints: MRD-negativity…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.